SCHEMBL21458140

SCHEMBL21458140

COC(=O)C1CC2(CC(NC(=O)c3ccc(Cl)c4cnn(Cc5ccc6nc(OC)ccc6c5)c34)C2)C1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 2/20 0.35
PTGER4 P35408 1/20 0.34
TNF P01375 1/20 0.34
IRAK4 Q9NWZ3 1/20 0.34
ROCK2 O75116 3/20 0.34
HPGDS O60760 1/20 0.34
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
CRHR1 P34998 1/20 0.33
EGFR P00533 2/20 0.32
KLKB1 P03952 2/20 0.32
KLK1 P06870 1/20 0.32
CCR3 P51677 1/20 0.32
MCHR1 Q99705 1/20 0.32
ENPP2 Q13822 1/20 0.32
ATXN2 Q99700 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21481962 1.00 CHRM4 (0.35) CHRM4PTGER4TNFIRAK4ROCK2
SCHEMBL30843267 0.94 PTGER4 (0.40) CHRM4PTGER4ROCK2HPGDSCNR1
SCHEMBL21458242 0.94 PTGER4 (0.40) CHRM4PTGER4ROCK2HPGDSCNR1
SCHEMBL24992167 0.90 CRHR1 (0.39) CHRM4HPGDSCNR1CNR2CRHR1
SCHEMBL21458215 0.89 PTGER4 (0.41) CHRM4PTGER4ROCK2HPGDSCNR1
SCHEMBL22927045 0.89 PTGER4 (0.41) CHRM4PTGER4ROCK2HPGDSCNR1
SCHEMBL21481972 0.85 CNR2 (0.33) CHRM4PTGER4ROCK2HPGDSCNR1
SCHEMBL21458303 0.85 CNR2 (0.33) CHRM4PTGER4ROCK2HPGDSCNR1
SCHEMBL30843277 0.85 CNR2 (0.33) CHRM4PTGER4ROCK2HPGDSCNR1
SCHEMBL24992478 0.83 PTGER4 (0.36) PTGER4TNFIRAK4ROCK2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2025-11-20 US disclosed
US-12215093-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2025-02-04 US disclosed
EP-3781550-B1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2024-10-30 EP disclosed
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2024-05-09 US disclosed
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 US disclosed
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2023-02-09 US disclosed
US-11472789-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2022-10-18 US disclosed
US-10968201-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2021-04-06 US disclosed
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 US disclosed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795156-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CHRM4 174/4885PTGER4 1/4885TNF 4412/4885
US-10968201-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CHRM4 174/4885PTGER4 1/4885TNF 4412/4885
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CHRM4 174/4885PTGER4 1/4885TNF 4412/4885
US-11472789-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CHRM4 174/4885PTGER4 1/4885TNF 4412/4885
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CHRM4 174/4885PTGER4 1/4885TNF 4412/4885
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CHRM4 174/4885PTGER4 1/4885TNF 4412/4885
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CHRM4 174/4885PTGER4 1/4885TNF 4412/4885
US-12215093-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CHRM4 174/4885PTGER4 1/4885TNF 4412/4885
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CHRM4 174/4885PTGER4 1/4885TNF 4412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.